The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom.
Kemin Industries (Des Moines, IA) has announced that it was granted a patent by the European Patent Office for its proprietary spearmint extract called Neumentix. The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom. The fourth patent filed and granted for the ingredient; it pertains to the ability of the extract to promote the growth of neurons.
The polyphenol-rich extract contains over 50 phenolic compounds, including rosmarinic, salvianolic and lithospermic acids. According to Kemin, Neumentix targets the hippocampus, promoting neurogenesis to supporting one’s ability to learn, manage information, and react.
“Our research has indicated that Neumentix, sourced from patented plants and characterized by its phenolic complex, works to nourish the neurons in the brain and may increase new neural growth in specific areas of the brain, providing an important source of neuronutrition to fuel brain performance in healthy adults.” said Brenda Fonseca, global technical services lead, Kemin Human Nutrition and Health, in a press release. Fonseca is also an inventor listed on the patent.
"Backed by over 19 peer-reviewed scientific publications covering clinical and preclinical research, as well as spearmint plant features, Neumentix is a great choice for manufacturers looking to formulate with safe, sustainable and scientifically backed brain health ingredients to help promote new neuronal growth,” added Fonseca.
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.
What's next for NPA and CRN in their complaints against New York state?
May 2nd 2024The latest updates in the efforts of the Natural Products Association and the Council for Responsible Nutrition to sue New York state for its law banning the sale of weight management and muscle building supplements to minors.